Inhibrx Biosciences, Inc. (NASDAQ:INBX) — Market Cap & Net Worth
Market Cap & Net Worth: Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (NASDAQ:INBX) has a market capitalization of $1.30 Billion ($1.30 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7793 globally and #2320 in its home market, demonstrating a -7.20% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Inhibrx Biosciences, Inc.'s stock price $104.73 by its total outstanding shares 14671186 (14.67 Million). Also see INBX total assets for a full breakdown of the balance sheet.
Inhibrx Biosciences, Inc. Market Cap History: 2020 to 2026
Inhibrx Biosciences, Inc.'s market capitalization history from 2020 to 2026. Data shows growth from $483.71 Million to $1.54 Billion (30.62% CAGR). Also see INBX operating cash flow for how efficiently the company converts equity into cash flow.
Index Memberships
Inhibrx Biosciences, Inc. is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.05% | #229 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #860 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.07% | #135 of 263 |
Weight: Inhibrx Biosciences, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Inhibrx Biosciences, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Inhibrx Biosciences, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check INBX live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
891.56x
Inhibrx Biosciences, Inc.'s market cap is 891.56 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $483.71 Million | $12.81 Million | -$75.64 Million | 37.77x | N/A |
| 2021 | $640.69 Million | $7.12 Million | -$81.77 Million | 89.92x | N/A |
| 2022 | $361.50 Million | $2.19 Million | -$145.23 Million | 164.92x | N/A |
| 2023 | $557.51 Million | $1.80 Million | -$241.36 Million | 309.73x | N/A |
| 2024 | $225.94 Million | $200.00K | $1.69 Billion | 1129.68x | 0.13x |
| 2025 | $1.16 Billion | $1.30 Million | -$140.06 Million | 891.56x | N/A |
Competitor Companies of INBX by Market Capitalization
Companies near Inhibrx Biosciences, Inc. in the global market cap rankings as of September 18, 2026. Review INBX goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Inhibrx Biosciences, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Inhibrx Biosciences, Inc. Historical Marketcap From 2020 to 2026
Between 2020 and today, Inhibrx Biosciences, Inc.'s market cap moved from $483.71 Million to $ 1.54 Billion, with a yearly change of 30.62%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.54 Billion | +32.57% |
| 2025 | $1.16 Billion | +412.99% |
| 2024 | $225.94 Million | -59.47% |
| 2023 | $557.51 Million | +54.22% |
| 2022 | $361.50 Million | -43.58% |
| 2021 | $640.69 Million | +32.45% |
| 2020 | $483.71 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Inhibrx Biosciences, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.30 Billion USD |
| MoneyControl | $1.30 Billion USD |
| MarketWatch | $1.30 Billion USD |
| marketcap.company | $1.30 Billion USD |
| Reuters | $1.30 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-bas… Read more